CRISPR-Associated Nucleases for Gene Editing | Max Sellman
Presented by Max Sellman, Product Manager, Gene Editing.
High-quality CRISPR nucleases are critical to advancing next-generation cell therapies. Max Sellman highlights the efforts at Aldevron to develop robust manufacturing processes and quality control assays for clinical-grade SpCas9 nuclease.
To learn more, visit http://www.aldevron.com/cas9.
#Aldevron #Biotechnology #CRISPR #genetherapy #celltherapy